immuven
Immuven featured a powerful, emerging life science technology -- high-affinity T cell receptors, a novel class of immune-targeting drugs and diagnostic agents. ImmuVen, Inc. was acquired by a major pharmaceutical company in December, 2014.
Immuven featured a powerful, emerging life science technology -- high-affinity T cell receptors, a novel class of immune-targeting drugs and diagnostic agents. ImmuVen, Inc. was acquired by a major pharmaceutical company in December, 2014.
